WO2010078421A8 - Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds - Google Patents

Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds Download PDF

Info

Publication number
WO2010078421A8
WO2010078421A8 PCT/US2009/069813 US2009069813W WO2010078421A8 WO 2010078421 A8 WO2010078421 A8 WO 2010078421A8 US 2009069813 W US2009069813 W US 2009069813W WO 2010078421 A8 WO2010078421 A8 WO 2010078421A8
Authority
WO
WIPO (PCT)
Prior art keywords
phenylbenzo
isoquinolin
dihydro
substituted
amine compounds
Prior art date
Application number
PCT/US2009/069813
Other languages
French (fr)
Other versions
WO2010078421A1 (en
Inventor
Syed M. Ali
Mark Ashwell
Manish Tandon
Rui-Yang Yang
Yanbin Liu
David Vensel
Sudharshan Eathiraj
Rocio Palma
Jean-Marc Lapierre
Neil Westlund
Hui Wu
Nivedita Namdev
Eugene Kelleher
Original Assignee
Arqule, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0923786A priority Critical patent/BRPI0923786C8/en
Priority to MX2011006959A priority patent/MX2011006959A/en
Priority to ES09793690.0T priority patent/ES2554623T3/en
Priority to CN200980156889.XA priority patent/CN102325755B/en
Priority to JP2011544603A priority patent/JP5739820B2/en
Priority to DK09793690.0T priority patent/DK2379506T3/en
Priority to EP09793690.0A priority patent/EP2379506B1/en
Priority to AU2009335010A priority patent/AU2009335010B2/en
Application filed by Arqule, Inc. filed Critical Arqule, Inc.
Priority to CA2748491A priority patent/CA2748491C/en
Priority to KR1020117017777A priority patent/KR101714799B1/en
Publication of WO2010078421A1 publication Critical patent/WO2010078421A1/en
Priority to ZA2011/04706A priority patent/ZA201104706B/en
Priority to IL213787A priority patent/IL213787A/en
Publication of WO2010078421A8 publication Critical patent/WO2010078421A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Abstract

The present invention relates to substituted 5,6-dihydro-6- phenylbenzo[f]isoquinolin-2-amine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
PCT/US2009/069813 2008-12-30 2009-12-30 Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds WO2010078421A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP09793690.0A EP2379506B1 (en) 2008-12-30 2009-12-30 Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
ES09793690.0T ES2554623T3 (en) 2008-12-30 2009-12-30 Compounds of substituted 5,6-dihydro-6-phenylbenzo [f] isoquinolin-2-amine
CN200980156889.XA CN102325755B (en) 2008-12-30 2009-12-30 Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
JP2011544603A JP5739820B2 (en) 2008-12-30 2009-12-30 Substituted 5,6-dihydro-6-phenylbenzo [f] isoquinolin-2-amine compounds
DK09793690.0T DK2379506T3 (en) 2008-12-30 2009-12-30 Substituted 5,6-dihydro-6-phenylbenzo [f] isoquinolin-2-amine compounds
BRPI0923786A BRPI0923786C8 (en) 2008-12-30 2009-12-30 5,6-dihydro-6-phenylbenzo(f)isoquinoline-2-amine substituted compounds and pharmaceutical compositions comprising said compounds
AU2009335010A AU2009335010B2 (en) 2008-12-30 2009-12-30 Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
MX2011006959A MX2011006959A (en) 2008-12-30 2009-12-30 Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds.
CA2748491A CA2748491C (en) 2008-12-30 2009-12-30 Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
KR1020117017777A KR101714799B1 (en) 2008-12-30 2009-12-30 Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
ZA2011/04706A ZA201104706B (en) 2008-12-30 2011-06-24 Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
IL213787A IL213787A (en) 2008-12-30 2011-06-27 Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14143908P 2008-12-30 2008-12-30
US61/141,439 2008-12-30
US26050509P 2009-11-12 2009-11-12
US61/260,505 2009-11-12

Publications (2)

Publication Number Publication Date
WO2010078421A1 WO2010078421A1 (en) 2010-07-08
WO2010078421A8 true WO2010078421A8 (en) 2011-10-27

Family

ID=41682678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/069813 WO2010078421A1 (en) 2008-12-30 2009-12-30 Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds

Country Status (14)

Country Link
US (1) US8357694B2 (en)
EP (1) EP2379506B1 (en)
JP (1) JP5739820B2 (en)
KR (1) KR101714799B1 (en)
CN (1) CN102325755B (en)
BR (1) BRPI0923786C8 (en)
CA (1) CA2748491C (en)
DK (1) DK2379506T3 (en)
ES (1) ES2554623T3 (en)
IL (1) IL213787A (en)
MX (1) MX2011006959A (en)
TW (1) TWI461410B (en)
WO (1) WO2010078421A1 (en)
ZA (1) ZA201104706B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CA2841629A1 (en) * 2011-07-15 2013-01-24 Abbvie Inc. Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
GB2499666A (en) * 2012-02-27 2013-08-28 Nanyang Polytechnic Mcl-1 inhibitors for the treatment of conditions associated with proliferative disorders
HUE042374T2 (en) 2012-06-13 2019-06-28 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (en) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR
EA035095B1 (en) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Bicyclic heterocycles as fgfr inhibitors
CA2956270C (en) 2014-08-18 2022-08-09 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
BR112017004459A2 (en) 2014-09-05 2017-12-05 Arqule Inc compositions and methods for treating proliferation disorders
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN113004278B (en) 2015-02-20 2023-07-21 因赛特控股公司 Bicyclic heterocycles as FGFR inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
MX2021000432A (en) * 2015-12-17 2022-07-28 Arqule Inc Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinoli n-2-amine compounds.
BR112018012325A2 (en) * 2015-12-17 2018-12-04 Arqule Inc methods for preparing substituted 5,6-dihydro-6-phenylbenzo [f] isoquinolin-2-amine
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
CA3091153A1 (en) 2018-03-28 2019-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
AU2019262195A1 (en) 2018-05-04 2020-12-24 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
AU2019262579A1 (en) 2018-05-04 2020-12-24 Incyte Corporation Salts of an FGFR inhibitor
CN110669015A (en) * 2018-07-03 2020-01-10 上海喀露蓝科技有限公司 Preparation method of FGFR inhibitor
CA3114147A1 (en) 2018-09-27 2020-04-02 Betta Pharmaceuticals Co., Ltd Fgfr4 inhibitor and use thereof
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022007163A2 (en) 2019-10-14 2022-08-23 Incyte Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505258A (en) 2019-12-04 2023-02-08 インサイト・コーポレイション Tricyclic heterocycles as FGFR inhibitors
KR20220131900A (en) 2019-12-04 2022-09-29 인사이트 코포레이션 Derivatives of FGFR inhibitors
US20230416271A1 (en) * 2020-11-26 2023-12-28 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Heteroarylquinazoline compounds as protein kinase inhibitors
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN113354630B (en) * 2021-06-30 2022-11-01 江南大学 5,6-dihydrobenzo [ h ] quinazoline compound and application thereof
TW202334097A (en) * 2021-10-25 2023-09-01 美商雷度納製藥公司 Benzo[h]quinazoline-4-amine derivatives for the treatment of cancer
WO2023196629A1 (en) * 2022-04-07 2023-10-12 Redona Therapeutics, Inc. Benzo[h]quinazoline-4-amine derivatives for the treatment of cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2623846A1 (en) 1976-05-28 1977-12-15 Hoechst Ag 4-QUINAZOLINYL GUANIDINE AND THE METHOD OF MANUFACTURING IT
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1154024B (en) 1982-09-22 1987-01-21 Lepetit Spa PRIDINICAL DERIVATIVES AND PROCEDURE FOR THEIR PRODUCTION
US4625026A (en) 1982-12-30 1986-11-25 Biomeasure, Inc. 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections
US4814335A (en) 1982-12-30 1989-03-21 Biomeasure, Incorporated Antiviral compounds
DD240010A1 (en) 1985-03-22 1986-10-15 Univ Berlin Humboldt PROCESS FOR PREPARING SUBSTITUTED 2-IMINO-1H-PYRIDINE-1-AMINES
SU1540240A1 (en) 1988-05-16 1995-09-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 5-substituted 1-amino-8,9- dihydro-8,8- dimethyl-3,6h- pyrazolo-[3, 4-b]- pyrano-[4',3'-d]- pyridine or their hydrochlorides showing anticonvulsant activity
DD280109A1 (en) 1989-02-22 1990-06-27 Univ Berlin Humboldt PROCESS FOR PREPARING SUBSTITUTED 1,2,4-TRIAZOLO / 1.5-A / PYRIDINES
SU1626648A1 (en) 1989-07-20 1995-09-27 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 1-AMINO-8,9-DIHYDRO-5,8,8-TRIMETHYL-3,6H-PYRAZOLO(3,4-b)THIOP- YRANO(4, 3-D)PYRIDINE OR ITS HYDROCHLORIDE SHOWING ANTICONVULSANT ACTIVITY
DE4117802A1 (en) 1991-05-30 1992-12-03 Berlin Chemie Ag New 2-amino-pyridin-3-carbo:nitrile derivs. - used for treatment of human cytomegalovirus
AU7831694A (en) 1993-09-24 1995-04-10 Du Pont Merck Pharmaceutical Company, The Improved methods for preparing bis-imide compounds
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
IL123581A (en) * 1995-10-02 2001-09-13 Hoffmann La Roche PYRIMIDINE DERIVATIVES AS 5HT2c-RECEPTOR ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
WO2001072710A1 (en) 2000-03-31 2001-10-04 Nippon Shinyaku Co., Ltd. Heterocycle derivatives and drugs
WO2002074341A1 (en) 2001-03-19 2002-09-26 Nippon Shinyaku Co., Ltd. Antipruritics
WO2005014727A1 (en) 2003-07-17 2005-02-17 Ciba Specialty Chemicals Holding Inc. Black pigment compositions
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
CN1897950A (en) * 2003-10-14 2007-01-17 惠氏公司 Fused-aryl and heteroaryl derivatives and methods of their use
US7244844B2 (en) 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
EP1773840B1 (en) 2004-07-23 2010-01-20 The Medicines Company (Leipzig) GmbH Substituted pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and pyrido[3',2':4,5]furo[3,2-d]-pyrimidines for use as inhibitors of pda-4 and/or tnf-alpha release
JP4171061B2 (en) 2005-02-09 2008-10-22 アーキュール，インコーポレーテッド Maleimide derivatives, pharmaceutical compositions and their use for the treatment of cancer
AU2005335876A1 (en) 2005-08-24 2007-03-01 Protherics Medicines Development Limited Cleavage of antifolate compounds
ES2587827T3 (en) 2006-02-15 2016-10-27 Abbvie Inc. Pyrazoloquinolones are potent PARP inhibitors
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
WO2008083356A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors

Also Published As

Publication number Publication date
US20100239525A1 (en) 2010-09-23
MX2011006959A (en) 2011-12-06
EP2379506B1 (en) 2015-09-02
AU2009335010A1 (en) 2011-07-21
JP5739820B2 (en) 2015-06-24
EP2379506A1 (en) 2011-10-26
BRPI0923786B1 (en) 2020-11-24
IL213787A (en) 2014-08-31
CA2748491A1 (en) 2010-07-08
WO2010078421A1 (en) 2010-07-08
ZA201104706B (en) 2012-08-29
US8357694B2 (en) 2013-01-22
KR20110099790A (en) 2011-09-08
TWI461410B (en) 2014-11-21
ES2554623T3 (en) 2015-12-22
JP2012514045A (en) 2012-06-21
DK2379506T3 (en) 2015-12-14
BRPI0923786C8 (en) 2021-05-25
CN102325755B (en) 2015-07-01
BRPI0923786C1 (en) 2021-05-11
AU2009335010A8 (en) 2011-08-11
KR101714799B1 (en) 2017-03-09
CN102325755A (en) 2012-01-18
CA2748491C (en) 2019-08-06
IL213787A0 (en) 2011-07-31
BRPI0923786A2 (en) 2016-07-26
TW201035055A (en) 2010-10-01

Similar Documents

Publication Publication Date Title
WO2010078421A8 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
WO2011082266A3 (en) Substituted heterocyclic compounds
WO2012177844A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
MX2007009649A (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer.
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
WO2012075492A3 (en) Carbocycle-substituted purine and 7-deazapurine compounds
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
WO2008097640A3 (en) Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2009153496A3 (en) Ppar agonist compounds and preparation and uses thereof for treating diabetes and/or dyslipidemia
WO2006034154A3 (en) Salts of 5-azacytidine
WO2009002808A3 (en) Quinazolinone compounds and methods of use thereof
WO2009151598A8 (en) Diazacarbazoles and methods of use
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
WO2010067078A8 (en) 3,6-disubstituted xanthylium salts
WO2012061342A3 (en) Substituted benzo-imidazo-pyrido-diazepine compounds
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980156889.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09793690

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009335010

Country of ref document: AU

Ref document number: 2748491

Country of ref document: CA

Ref document number: MX/A/2011/006959

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2011544603

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2700/KOLNP/2011

Country of ref document: IN

Ref document number: 12011501340

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2009793690

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009335010

Country of ref document: AU

Date of ref document: 20091230

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117017777

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI0923786

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI0923786

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110629